Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. . Lancet 2022;399:665-676.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2022;399:665-676.
PMID: 35151397